UBT251 vs HM15211

Head-to-head comparison of UBT251 (UBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) and HM15211 (HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyUBT251HM15211
CategoryWeight ManagementWeight Management
Full NameUBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonistHM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist
Molecular WeightN/AN/A
Half-LifeApproximately 1 weekApproximately 1 week
Amino AcidsN/AN/A
Typical DoseInvestigational; no established human doseInvestigational; no established human dose
RouteSubcutaneousSubcutaneous
Purity≥98%≥98%
Studies Count812
Research StatusPre-clinicalClinical

UBT251 Benefits

  • weight reduction
  • improved satiety
  • enhanced energy expenditure
  • better insulin sensitivity

HM15211 Benefits

  • appetite suppression
  • greater fat oxidation
  • weight loss
  • improved metabolic markers

UBT251 Dosing

once-weekly subcutaneous injection|dose escalation in studies|maintenance after tolerability assessment

HM15211 Dosing

once-weekly subcutaneous injection|titration to effect|maintenance at tolerated dose

UBT251 Side Effects

  • nausea
  • diarrhea
  • fatigue

HM15211 Side Effects

  • nausea
  • vomiting
  • reduced appetite

Research Overview

UBT251

Published work supports strong anti-obesity activity in preclinical models, with translation into human studies still emerging. The compound remains investigational and is best characterized as an early multi-agonist program.

HM15211

Research has shown potent weight-reducing and metabolic effects in preclinical and translational studies. The compound is being developed as a next-generation incretin-based therapy.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

UBT251 stacks with:

metforminorlistat

HM15211 stacks with:

metformintopiramate
glp1gipglucagontriagonistweight-managementobesity